2Yang W, Lu J, Weng J, et al. Prevalence of diabetes among men and women in China. N Engl J Med,2010,362(3) :1090-1101.
3Stratton IM,Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35 ) : prospective observational study. BMJ, 2000, 321 (7258) :405-412.
4Simsek S, Schalkwijk CG, Wolffenbuttel BHR. Short Report : Treat- ment Effects of rosuvastalin and atorvastatin on glycaemic control in Type 2 diabetes-the CORALL study. DIABETIC Medicine,2011: 628-631.
5Qaseem A,Humphrey LI,,Sweet DE ,et al. Oral pharmacologic treat- ment of type 2 diabetes mellitus:a clinical practice guideline from the american college of physicians. Ann Inter Med, 2012,156 (3) : 218-231.
6Bennett WL, Maruthur NM, Siugh S, et al. Comparative effective- ness and safety of medications for type 2 diabetes : an update inclu- ding new drugs and 2-drug combinations. Ann Inter Med, 2011 , 154(9) :602-613.
7Hasegawa G, Kajiyama S, Tanaka T, et al. The ct-glueosidase inhib- itor acarbose reduces the net electronegative charge of low-density lipoprotein in patients with newly diagnosed type 2 diabetes. Ctini- ca Chimica Acta,2008,390 (2) : 110-114.
8Pan C,Yang W,Jia W,et al.Management of Chinese patients with type 2 diabetes,1998-2006:the DiabcareChina surveys[J].Current Medical Research,2009,25(1):39.
9All S,Stone M,Skinner T C,et al.The association between depression and health-related quality of life in people with type 2 diabetes:a systematic literature review[J].Diabetes Metab Res Rev,2010,26(2):75.
10World Health Organization.Definition,diagnosis and classification of diabetes mellitus and its complications.In:Report of a WHO Consultation[C].WHO/NCD/NCS/99.2.Geneva:WHO,1999.
